ANACETRAPIB ( DrugBank: Anacetrapib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 79 | Homozygous familial hypercholesterolemia | 5 |
79. Homozygous familial hypercholesterolemia
Clinical trials : 145 / Drugs : 114 - (DrugBank : 26) / Drug target genes : 8 - Drug target pathways : 17
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-002434-37-IT (EUCTR) | 16/07/2013 | 05/06/2013 | n.a. | A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-WeekStudy to Assess the Efficacy and Tolerability of Anacetrapib When Added to OngoingLipid-Lowering Therapy in Adult Patients with Homozygous FamilialHypercholesterolemia (HoFH) - n.a. | Homozygous Familial Hypercholesterolemia (HoFH) MedDRA version: 14.1;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Anacetrapib Product Code: MK-0859 INN or Proposed INN: ANACETRAPIB Other descriptive name: ANACETRAPIB | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | NULL | Not Recruiting | Female: yes Male: yes | 45 | Phase 3 | United States;Czech Republic;Canada;Malaysia;Brazil;Israel;South Africa;Norway;United Kingdom;Italy | ||
| 2 | EUCTR2012-002434-37-CZ (EUCTR) | 13/06/2013 | 28/12/2012 | n/a | A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-WeekStudy to Assess the Efficacy and Tolerability of Anacetrapib When Added to OngoingLipid-Lowering Therapy in Adult Patients with Homozygous FamilialHypercholesterolemia (HoFH) with a 52-Week Open-Label Extension | Homozygous Familial Hypercholesterolemia (HoFH);Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: MK-0859 Product Code: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | NULL | Not Recruiting | Female: yes Male: yes | 45 | United States;Czech Republic;Canada;Malaysia;Australia;Israel;South Africa;Norway;United Kingdom | |||
| 3 | NCT01841684 (ClinicalTrials.gov) | June 2013 | 24/4/2013 | Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) | A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH) | Hyperlipoproteinemia Type II;Homozygous Familial Hypercholesterolemia | Drug: Anacetrapib;Drug: Placebo | Merck Sharp & Dohme Corp. | NULL | Terminated | 18 Years | N/A | Both | 2 | Phase 3 | United States;Canada;Germany;Israel;Italy;United Kingdom;Norway |
| 4 | EUCTR2012-002434-37-GB (EUCTR) | 23/05/2013 | 23/11/2012 | n/a | A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients with Homozygous Familial Hypercholesterolemia (HoFH) with a 52-Week Open-Label Extension - Anacetrapib in Patients with Homozygous Familial Hypercholesterolemia | Homozygous Familial Hypercholesterolemia (HoFH);Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: MK-0859 Product Code: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | NULL | Not Recruiting | Female: yes Male: yes | 45 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Czech Republic;Canada;Malaysia;Australia;Israel;South Africa;Norway;Italy;United Kingdom | ||
| 5 | EUCTR2012-002434-37-NO (EUCTR) | 21/11/2012 | 26/11/2012 | n/a | A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-WeekStudy to Assess the Efficacy and Tolerability of Anacetrapib When Added to OngoingLipid-Lowering Therapy in Adult Patients with Homozygous FamilialHypercholesterolemia (HoFH) with a 52-Week Open-Label Extension | Homozygous Familial Hypercholesterolemia (HoFH);Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: MK-0859 Product Code: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | NULL | Not Recruiting | Female: yes Male: yes | 45 | United States;Czech Republic;Canada;Malaysia;Australia;Israel;South Africa;Norway;United Kingdom |